Search the webpage

Category: Angiogenesis

The inhibition of vascular endothelial cell growth factor A (VEGF) pathway in in vitro proliferation assay is an integral part of the potency assessment of VEGF inhibitor candidates for intraocular vascular diseases. The primary bovine retinal endothelium cells (BRECs) are physiologically relevant cells to assess the angiogenesis.

SUMMARY

Cells

Primary bovine retinal endothelium cells (BRECs)

Induction

rhVEGF165

Positive control

Aflibercept (Eylea®) at 0.01 to 30 nM

Indicator and detection

Indicator: resazurin (7-Hydroxy-3H-phenoxazin-3-one-10-oxide) dye is irreversibly reduced to highly fluorescent metabolite resorufin (7-Hydroxy-3H-phenoxazin-3-one); (Hakkarainen et al., 2016).

 

Detection: After 2 h exposure to resazurin, the amount of resorufin is measured at 560 nm (ex), 590 nm (em) by using Cytation 3 multi-mode reader (BioTek Instruments, Winooski, VT, USA); (Hakkarainen et al., 2016).

Please contact us, if you would like to receive more information: info@experimentica.com

IMAGES

Representative examples of assays on BRECs

Typical endothelial cell morphology of BRECs at DIV6 (left) and DIV7 (right). Scale bar 100 µm. BREC proliferation assay validation was performed as previously described (Yang et al., 2014). The half maximal inhibitory concentration (IC50) of VEGF inhibitor (aflibercept, Eylea®) was assessed using two commercially available rhVEGF165 (R&D Systems and Life Technologies).

A dose-dependent inhibition of rhVEGF-induced (R&D Systems and Life Technologies) BREC proliferation by aflibercept (Eylea®) at concentrations 0.01 to 30 nM. The figure on the left shows proliferative activity of rhVEGF on BREC from R&D Systems and Life Technologies. rhVEGF from R&D Systems seems to enhance the BRECs proliferation more efficienthly than rh VEGF from Life Technologies. Therefore, the higher IC50 value is a result from enhanced BREC proliferation.

SELECTED PUBLICATIONS

  1. Yang J, Wang X, Fuh G, Yu L, Wakshull E, Khosraviani M, Day ES, Demeule B, Liu J, Shire SJ, Ferrara N, Yadav S. Comparison of binding characteristics and in vitro activities of three inhibitors of vascular endothelial growth factor A. Mol Pharm 2014,11(10):3421-3430. doi: 10.1021/mp500160v.

REFERENCES

  1. Hakkarainen JJ, Reinisalo M, Ragauskas S, Seppänen A, Kaja S, Kalesnykas G. Acute cytotoxic effects of marketed ophthalmic formulations on human corneal epithelial cells. Int J Pharm. 2016;511(1):73-78. doi: 10.1016/j.ijpharm.2016.06.135

LATEST NEWS

A retinal organotypic model for ex vivo neuroprotection studies

News
A recently published study by Experimentica Ltd. and its collaborators from the University of Tampere, Finland, shows that when the ... Read More

Thank you for visiting us at ARVO 2019 conference

News
Created by Simon Kaja on   June 5, 2019   in category: News Thank you, everyone, for visiting our booth at ARVO 2019 in Vancouver, Canada, ... Read More

Meet Experimentica team at ARVO 2019

News
Visit our booth #1354 or email to set up a one-on-one meeting ... Read More

Subscribe to Our Newsletter!

We promise that no sales pitches will be attached to newsletter. And don't worry, we hate spammers too!